Table 2.
Univariate Analysis of the Study Patients (N = 80): Clinical and Radiographic Factors
| Feature | n | OR | 95% CI | P |
|---|---|---|---|---|
| Age | — | 0.8797417 | 0.84–0.92 | <.0001 |
| Sex | ||||
| Female | 30 | — | — | .0164 |
| Male | 50 | 0.3437707 | 0.14–0.85 | |
| KPS score | — | 1.0853484 | 1.04–1.14 | <.0001 |
| T1-enhancing volume | — | 0.9839941 | 0.97–1.00 | .0497 |
| T2 volume including T1 | — | 1.0027202 | 1.00–1.01 | .4802 |
| T1/T2 volumetric ratio | — | 0.0807405 | 0.01–0.45 | .0022 |
| Necrosis volume | — | 0.9699149 | 0.93–1.01 | .0817 |
| Volumetric EOR based on enhancement | — | 1.0087027 | 0.96–1.06 | .7141 |
| Volumetric EOR based on T2/FLAIR disease | — | 0.9947252 | 0.98–1.01 | .5930 |
| EOR based on enhancing disease | ||||
| GTR | 57 | — | — | .3419 |
| STR | 16 | 0.4584197 | 0.15–1.40 | |
| Biopsy | 3 | 0.5608276 | 0.04–7.37 | |
| PD-L1 status | ||||
| Negative | 46 | — | — | .7869 |
| Positive | 6 | 0.7866907 | 0.13–4.75 | |
| TMB | — | 0.7378053 | 0.58–0.94 | .0055 |
| Clinical trial enrollment | — | |||
| No | 54 | — | — | <.0001 |
| Yes | 25 | 6.5197993 | 2.51–16.92 | |
| MGMT methylation | ||||
| No | 38 | — | — | .0032 |
| Yes | 32 | 3.9444285 | 1.52–10.22 |
KPS, Karnofsky Performance Scale; EOR, extent of resection; GTR, gross total resection; STR, subtotal resection; TMB, tumor mutational burden.